A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer
GU006 permanently closed to accrual, effective May 19, 2020, because it has reached its accrual target.
